116 related articles for article (PubMed ID: 35568074)
1. Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment.
Li J; Cao P; Chen Y; Wang J; Sun X; Chen R; Wang G; Hou J
Exp Cell Res; 2022 Aug; 417(1):113197. PubMed ID: 35568074
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib enhanced CD8
Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer.
Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z
Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.
Yang Y; Li L; Jiang Z; Wang B; Pan Z
Cancer Immunol Immunother; 2020 Dec; 69(12):2523-2532. PubMed ID: 32577817
[TBL] [Abstract][Full Text] [Related]
5. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
6. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Liu S; Qin T; Liu Z; Wang J; Jia Y; Feng Y; Gao Y; Li K
Cell Death Dis; 2020 May; 11(5):309. PubMed ID: 32366856
[TBL] [Abstract][Full Text] [Related]
7. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
[TBL] [Abstract][Full Text] [Related]
9. Combination of radiotherapy and Anlotinib enhances benefit from immunotherapy to liver metastasis and abscopal tumor from lung cancer.
Jiang Y; Qiao S; Li L; Zhu X
Int Immunopharmacol; 2024 Feb; 128():111441. PubMed ID: 38171056
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING/IFN-β pathway.
Yuan M; Guo XL; Chen JH; He Y; Liu ZQ; Zhang HP; Ren J; Xu Q
Neoplasma; 2022 Jul; 69(4):807-819. PubMed ID: 35471977
[TBL] [Abstract][Full Text] [Related]
11. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP
Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Experienced Human NK Cells Express High Levels of PD-L1 and Inhibit CD8
Sierra JM; Secchiari F; Nuñez SY; Iraolagoitia XLR; Ziblat A; Friedrich AD; Regge MV; Santilli MC; Torres NI; Gantov M; Trotta A; Ameri C; Vitagliano G; Pita HR; Rico L; Rovegno A; Richards N; Domaica CI; Zwirner NW; Fuertes MB
Front Immunol; 2021; 12():745939. PubMed ID: 34616407
[TBL] [Abstract][Full Text] [Related]
13. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.
Cui S
Med Sci Monit; 2017 Jul; 23():3360-3366. PubMed ID: 28697172
[TBL] [Abstract][Full Text] [Related]
15. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Hara T; Miyake H; Hinata N; Fujisawa M
Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
[TBL] [Abstract][Full Text] [Related]
19. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
[TBL] [Abstract][Full Text] [Related]
20. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]